Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy.

MLA

Franzè, S., et al. “Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy.” BioDrugs, vol. 29, no. 2, Apr. 2015, pp. 113–21. EBSCOhost, https://doi.org/10.1007/s40259-015-0121-x.

APA

Franzè, S., Cilurzo, F., & Minghetti, P. (2015). Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy. BioDrugs, 29(2), 113–121. https://doi.org/10.1007/s40259-015-0121-x

Chicago

Franzè, S., F. Cilurzo, and P. Minghetti. 2015. “Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy.” BioDrugs 29 (2): 113–21. doi:10.1007/s40259-015-0121-x.